Abstract
AimsHigher doses of the glucagon-like peptide-1 agonist semaglutide and, more recently, tirzepatide, a dual glucose-dependent insulinotropic polypepti......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
